Eagle Pharmaceuticals Equity 2024

Eagle Pharmaceuticals Aktienanalyse

What does Eagle Pharmaceuticals do?

Eagle Pharmaceuticals Inc was founded in 2007 and is based in New Jersey, USA. The company operates in the field of development and marketing of pharmaceutical products. History Eagle Pharmaceuticals was founded by Scott Tarriff, an experienced entrepreneur and expert in the fields of pharmacy and biotechnology. The goal was to create a company focused on developing generic drugs with improved effectiveness. Eagle Pharmaceuticals started with two products - Argatroban and Ryanodex. Argatroban is an anticoagulant used in the treatment of thrombosis. Ryanodex is a muscle relaxant for patients suffering from malignant hyperthermia. Business model Eagle Pharmaceuticals has a unique business model that sets it apart from other pharmaceutical companies. They focus on developing generic drugs with improved effectiveness instead of entirely new drugs. The company also focuses on licensing technologies rather than spending money on research and development. The company works closely with doctors and hospitals to ensure that their products meet the needs of patients. Divisions Eagle Pharmaceuticals is divided into two business segments - branded and generic products. Branded products: The company develops and distributes generic products with improved effectiveness. These include products such as Ryanodex, Bendeka, Belrapzo, and Pemetrexed. Generic products: The company has a wide range of generic products used in the areas of anticoagulants, oncology, and pain management. These include products such as Argatroban, Docetaxel, Phenylephrine HCl, and Bivalirudin. Products Argatroban: An anticoagulant used in patients with thrombosis or thromboembolic events. Ryanodex: A muscle relaxant used in patients suffering from malignant hyperthermia. Bendeka: A medication for leukemia used in combination with other chemotherapies. Belrapzo: A medication for certain types of cancer used in combination with other chemotherapies. Pemetrexed: A medication for various cancer diseases, such as lung and breast cancer. Docetaxel: A medication for various cancer diseases, such as breast cancer, lung cancer, and prostate cancer. Phenylephrine HCl: A medication for high blood pressure and bronchodilation. Bivalirudin: An anticoagulant used in patients undergoing angioplasty or coronary bypass surgery. In summary, Eagle Pharmaceuticals is an innovative pharmaceutical company that focuses on developing drugs with improved effectiveness. The company has a wide range of products in the areas of oncology, pain management, and anticoagulants. It works closely with doctors and hospitals to ensure that its products meet the needs of patients. Eagle Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Eagle Pharmaceuticals's Equity

Eagle Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Eagle Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Eagle Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Eagle Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Eagle Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Eagle Pharmaceuticals stock

What is the equity of Eagle Pharmaceuticals this year?

Eagle Pharmaceuticals has equity of 233.6 M USD this year.

What was the equity of Eagle Pharmaceuticals compared to the previous year?

The equity of Eagle Pharmaceuticals has increased/decreased by 32.35% increased compared to the previous year.

What impact does a high equity have on investors of Eagle Pharmaceuticals?

A high equity is advantageous for investors of Eagle Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Eagle Pharmaceuticals?

A low equity can be a risk for investors of Eagle Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Eagle Pharmaceuticals affect the company?

An increase in equity of Eagle Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Eagle Pharmaceuticals affect the company?

A reduction in equity of Eagle Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Eagle Pharmaceuticals?

Some factors that can affect the equity of Eagle Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Eagle Pharmaceuticals so important for investors?

The equity of Eagle Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Eagle Pharmaceuticals take to change the equity?

To change equity, Eagle Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Eagle Pharmaceuticals pay?

Over the past 12 months, Eagle Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Eagle Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Eagle Pharmaceuticals?

The current dividend yield of Eagle Pharmaceuticals is .

When does Eagle Pharmaceuticals pay dividends?

Eagle Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Eagle Pharmaceuticals?

Eagle Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Eagle Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Eagle Pharmaceuticals located?

Eagle Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Eagle Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Eagle Pharmaceuticals from 9/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.

When did Eagle Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/10/2024.

What was the dividend of Eagle Pharmaceuticals in the year 2023?

In the year 2023, Eagle Pharmaceuticals distributed 0 USD as dividends.

In which currency does Eagle Pharmaceuticals pay out the dividend?

The dividends of Eagle Pharmaceuticals are distributed in USD.